Eptinezumab
Calcitonin Gene-Related Peptide (Cgrp) Antagonists
Sold as VYEPTI
- Drug class
- Calcitonin Gene-Related Peptide (Cgrp) Antagonists
- Availability
- See label
- Routes
- Intravenous
- Markets covered
- 3
- Products on record
- 7
Overview
Eptinezumab is an active pharmaceutical ingredient in the Calcitonin Gene-Related Peptide (Cgrp) Antagonists group (N02CD). The information below is compiled per regulator from the product labels on record, with direct links to the original documents.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| GB United Kingdom | MHRA | 4 | October 3, 2025 |
| CA Canada | Health Canada | 2 | September 3, 2025 |
| EU European Union | EMA | 1 | May 29, 2026 |
GBUnited Kingdom· MHRA
4 products
Uses
VYEPTI is indicated for the prophylaxis of migraine in adults who have at least 4 migraine days per month.
How to take
CACanada· Health Canada
2 products
Uses
VYEPTI (eptinezumab for injection) is indicated for: • the prevention of migraine in adults who have at least 4 migraine days per month. Vyepti should be prescribed by healthcare professionals experienced in the diagnosis and treatment of migraine.
1 Pediatrics Pediatrics (< 18 years of age): No data are available in the pediatric population (< 18 years of age); therefore, Vyepti is not authorized for pediatric use. 2 Geriatrics Geriatrics (≥ 65 years of age): The safety and efficacy of Vyepti has not been established in patients aged 65 or older.
4 WARNINGS AND PRECAUTIONS, Special Populations, Geriatrics).
How to take
EUEuropean Union· EMA
1 product
Uses
VYEPTI is indicated for the prophylaxis of migraine in adults who have at least 4 migraine days per month.
How to take
Sources & citations
- [1]MHRA (UK) · PLGB004580314 · revised October 3, 2025
- [2]Health Canada (DPD) · 02510839 · revised September 3, 2025
- [3]European Medicines Agency · EMEA/H/C/005287 · revised May 29, 2026
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.